Alexion Reaches New 52-Week High (ALXN)

NEW YORK (TheStreet) -- Alexion Pharmaceuticals (Nasdaq:ALXN) hit a new 52-week high Thursday as it is currently trading at $81.75, above its previous 52-week high of $80.97 with 932,584 shares traded as of 10:19 a.m. ET. Average volume has been 1.2 million shares over the past 30 days.

Alexion has a market cap of $13.68 billion and is part of the health care sector and drugs industry. Shares are up 7.3% year to date as of the close of trading on Wednesday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company has a P/E ratio of 98.5, above the average drugs industry P/E ratio of 92.5 and above the S&P 500 P/E ratio of 17.7.

• Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Alexion as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Alexion Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

For more information on Alexion Pharmaceuticals Inc. click any of the following:

• Alexion Pharmaceuticals Inc. Stock Price

• Alexion Pharmaceuticals Inc. Analyst Ratings

• Alexion Pharmaceuticals Inc. Key Stats & Profile

• Alexion Pharmaceuticals Inc. Earnings

• Alexion Pharmaceuticals Inc. Ratio Comparison

• Alexion Pharmaceuticals Inc. Growth Rates

• Alexion Pharmaceuticals Inc. Balance Sheet

• Alexion Pharmaceuticals Inc. Cash Flow

• Alexion Pharmaceuticals Inc. Income Statement